Celyad Oncology SA - ADR Financials

$0.52

$-0.03 (-5.42%)

As on 20-Jul-2023 09:30EDT

Market cap

$14 Mln

Revenue (TTM)

$-- Mln

P/E Ratio

--

P/B Ratio

0.7

Div. Yield

0 %

Annual
Quarterly

Income Statement (€ Mln)	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Operating Revenue	--	--	0.01	0.01	3.12	3.54
Cost of Revenue	--	--	--	--	--	0.52
Gross Profit	--	--	0.01	0.01	3.12	3.03
Operating Expenses	20.26	26.91	26.24	29.38	34.50	29.82
Operating Profit (EBIT)	-40.86	-26.39	-26.24	-29.37	-38.17	-52.88
Other Income	--	--	--	--	--	--
Profit before Tax	-40.87	-26.50	-17.20	-28.64	-37.43	-56.40
Provision for Tax	0.07	0.01	0.30	-0.01	0.81	0.00
Profit after Tax (Net Income)	-40.94	-26.51	-17.50	-28.63	-37.43	-56.40
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	-26.51	-17.20	-28.63	-37.43	-56.40

Liabilities (€ Mln)	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Shareholder's Funds	4.32	43.64	30.99	45.62	55.59	47.54
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	4.97	22.48	23.26	32.30	29.06	22.15
Current Liabilities	10.43	13.83	11.83	11.92	9.65	7.95
Total Liabilities	19.72	79.94	66.08	89.84	94.30	77.63

Assets (€ Mln)	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Non-Current Assets	4.89	45.65	46.38	47.00	42.61	41.23
Current Assets	14.83	34.29	19.71	42.84	51.69	36.39
Total Assets	19.72	79.94	66.08	89.84	94.30	77.63
Total Debt*	0.26	2.63	3.64	4.36	1.65	1.44
Net Current Assets	4.40	20.47	7.87	30.91	42.05	28.45

Cashflow (€ Mln)	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Cash From Operating Activities	-28.01	-26.64	-27.67	-28.20	-27.25	-44.44
Cash Flow from Investing Activities	--	-0.13	0.16	8.99	0.61	17.61
Cash from Financing Activities	3.24	39.52	5.40	18.28	43.93	0.61
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Adjusted EPS (€)	--	--	--	--	--	--
Cash EPS (€)	--	--	--	--	--	--
Adjusted Book Value (€)	--	--	--	--	--	--
Dividend per Share (€)	--	--	--	--	--	--
Cash Flow per Share (€)	--	--	--	--	--	--
Free Cash Flow per Share (€)	--	--	--	--	--	--

Profitability Ratios	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
ROCE (%)	-161.03	-65.54	-41.37	-53.41	-70.47	-79.80
ROE (%)	-170.72	-71.05	-45.69	-56.58	-72.58	-81.48
ROA (%)	-82.15	-36.31	-22.45	-31.10	-43.54	-52.11
EBIT Margin (%)	--	--	-524,780.00	-489,550.00	-1,199.52	-1,590.06
Net Margin (%)	--	--	-350,020.00	-477,200.00	-1,201.51	-1,593.08
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Revenue Growth (%)	--	-1.00	-0.17	-1.00	-0.12	-0.58
EBIT Growth (%)	-54.81	-0.58	10.67	21.39	33.62	-139.49
Net Profit Growth (%)	-54.40	-51.49	38.88	23.50	33.63	-138.90
EPS Growth (%)	--	--	--	--	--	--
Book Value Growth (%)	--	--	--	--	--	--

Solvency Ratios	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debt to Equity	0.06	0.06	0.12	0.10	0.03	0.03
Short term debt to equity ratio	0.03	0.02	0.04	0.03	0.01	0.01
Current Ratio	1.42	2.48	1.67	3.59	5.36	4.58
Quick Ratio	--	--	1.53	3.59	5.36	4.58
Interest Coverage	-207.40	-103.49	-88.35	-85.64	-602.66	-521.19

Operating Efficiency Ratios	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debtors to sales (%)	--	--	18,140.00	45,033.33	40.74	44.97
Asset Turnover	--	--	0.00	0.00	0.04	0.03
Receivable days	--	--	131,818.73	120,867.31	167.73	159.67
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	4,573.78
Cash Conversion Cycle	--	--	--	--	--	-4,414.11